Improving Circulation Half-Life of Therapeutic Candidate N-TIMP2 by Unfolded Peptide Extension

Overview

Journal Biomolecules

Publisher MDPI

Specialties Biochemistry
Molecular Biology

Date 2024 Sep 28

PMID 39334953

Authors

Jason Shirian

Alexandra Hockla

Justyna J Gleba

Matt Coban

Naama Rotenberg

Laura M Strik

Aylin Alasonyalilar Demirer

Matt L Pawlush

John A Copland

Evette S Radisky

Julia M Shifman

Affiliations

Soon will be listed here.

Abstract

Matrix metalloproteinases (MMPs) are significant drivers of many diseases, including cancer, and are established targets for drug development. Tissue inhibitors of metalloproteinases (TIMPs) are endogenous MMP inhibitors and are being pursued for the development of anti-MMP therapeutics. TIMPs possess many attractive properties for drug candidates, such as complete MMP inhibition, low toxicity, low immunogenicity, and high tissue permeability. However, a major challenge with TIMPs is their rapid clearance from the bloodstream due to their small size. This study explores a method for extending the plasma half-life of the N-terminal domain of TIMP2 (N-TIMP2) by appending it with a long, intrinsically unfolded tail containing Pro, Ala, and Thr (PATylation). We designed and produced two PATylated N-TIMP2 constructs with tail lengths of 100 and 200 amino acids (N-TIMP2-PAT and N-TIMP2-PAT). Both constructs demonstrated higher apparent molecular weights and retained high inhibitory activity against MMP-9. N-TIMP2-PAT significantly increased plasma half-life in mice compared to the non-PATylated variant, enhancing its therapeutic potential. PATylation offers distinct advantages for half-life extension, such as fully genetic encoding, monodispersion, and biodegradability. It can be easily applied to N-TIMP2 variants engineered for high affinity and selectivity toward individual MMPs, creating promising candidates for drug development against MMP-related diseases.

References

Vandenbroucke R, Libert C . Is there new hope for therapeutic matrix metalloproteinase inhibition?. Nat Rev Drug Discov. 2014; 13(12):904-27. DOI: 10.1038/nrd4390. View

Hua S, Qiu M, Chan E, Zhu L, Luo Y . Minimum length of sequence homology required for in vivo cloning by homologous recombination in yeast. Plasmid. 1997; 38(2):91-6. DOI: 10.1006/plas.1997.1305. View

Van Doren S, Wei S, Gao G, DaGue B, Palmier M, Bahudhanapati H . Inactivation of N-TIMP-1 by N-terminal acetylation when expressed in bacteria. Biopolymers. 2008; 89(11):960-8. PMC: 2804306. DOI: 10.1002/bip.21043. View

Norden A, Lapsley M, Lee P, Pusey C, Scheinman S, Tam F . Glomerular protein sieving and implications for renal failure in Fanconi syndrome. Kidney Int. 2001; 60(5):1885-92. DOI: 10.1046/j.1523-1755.2001.00016.x. View

Kumar V, Lee J, Clark R, Noakes P, Taylor S, Woodruff T . Preclinical Pharmacokinetics of Complement C5a Receptor Antagonists PMX53 and PMX205 in Mice. ACS Omega. 2020; 5(5):2345-2354. PMC: 7017397. DOI: 10.1021/acsomega.9b03735. View

Farkas E, Katz Y, Bhusare S, Reich R, Roschenthaler G, Konigsmann M . Carbamoylphosphonate-based matrix metalloproteinase inhibitor metal complexes: solution studies and stability constants. Towards a zinc-selective binding group. J Biol Inorg Chem. 2004; 9(3):307-15. DOI: 10.1007/s00775-004-0524-5. View

Radisky E, Raeeszadeh-Sarmazdeh M, Radisky D . Therapeutic Potential of Matrix Metalloproteinase Inhibition in Breast Cancer. J Cell Biochem. 2017; 118(11):3531-3548. PMC: 5621753. DOI: 10.1002/jcb.26185. View

Dove A . MMP inhibitors: glimmers of hope amidst clinical failures. Nat Med. 2002; 8(2):95. DOI: 10.1038/nm0202-95. View

Campestre C, Agamennone M, Tortorella P, Preziuso S, Biasone A, Gavuzzo E . N-Hydroxyurea as zinc binding group in matrix metalloproteinase inhibition: mode of binding in a complex with MMP-8. Bioorg Med Chem Lett. 2005; 16(1):20-4. DOI: 10.1016/j.bmcl.2005.09.057. View

10.

Vantourout J, Adusumalli S, Knouse K, Flood D, Ramirez A, Padial N . Serine-Selective Bioconjugation. J Am Chem Soc. 2020; 142(41):17236-17242. PMC: 8350984. DOI: 10.1021/jacs.0c05595. View

11.

Arkadash V, Yosef G, Shirian J, Cohen I, Horev Y, Grossman M . Development of High Affinity and High Specificity Inhibitors of Matrix Metalloproteinase 14 through Computational Design and Directed Evolution. J Biol Chem. 2017; 292(8):3481-3495. PMC: 5336179. DOI: 10.1074/jbc.M116.756718. View

12.

AlQahtani A, OConnor D, Domling A, Goda S . Strategies for the production of long-acting therapeutics and efficient drug delivery for cancer treatment. Biomed Pharmacother. 2019; 113:108750. DOI: 10.1016/j.biopha.2019.108750. View

13.

Lee M, Kim Y, Kim Y, Kwon S, Bang J, Lee S . Pharmacokinetics and biodistribution of human serum albumin-TIMP-2 fusion protein using near-infrared optical imaging. J Pharm Pharm Sci. 2011; 14(3):368-77. DOI: 10.18433/j3h88d. View

14.

Neumann U, Kubota H, Frei K, Ganu V, Leppert D . Characterization of Mca-Lys-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2, a fluorogenic substrate with increased specificity constants for collagenases and tumor necrosis factor converting enzyme. Anal Biochem. 2004; 328(2):166-73. DOI: 10.1016/j.ab.2003.12.035. View

15.

Overall C, Kleifeld O . Tumour microenvironment - opinion: validating matrix metalloproteinases as drug targets and anti-targets for cancer therapy. Nat Rev Cancer. 2006; 6(3):227-39. DOI: 10.1038/nrc1821. View

16.

Winer A, Adams S, Mignatti P . Matrix Metalloproteinase Inhibitors in Cancer Therapy: Turning Past Failures Into Future Successes. Mol Cancer Ther. 2018; 17(6):1147-1155. PMC: 5984693. DOI: 10.1158/1535-7163.MCT-17-0646. View

17.

Johnson K, Makanji Y, Temple-Smith P, Kelly E, Barton P, Al-Musawi S . Biological activity and in vivo half-life of pro-activin A in male rats. Mol Cell Endocrinol. 2015; 422:84-92. DOI: 10.1016/j.mce.2015.12.007. View

18.

Murphy D . Determination of accurate KI values for tight-binding enzyme inhibitors: an in silico study of experimental error and assay design. Anal Biochem. 2004; 327(1):61-7. DOI: 10.1016/j.ab.2003.12.018. View

19.

Bahudhanapati H, Zhang Y, Sidhu S, Brew K . Phage display of tissue inhibitor of metalloproteinases-2 (TIMP-2): identification of selective inhibitors of collagenase-1 (metalloproteinase 1 (MMP-1)). J Biol Chem. 2011; 286(36):31761-70. PMC: 3173135. DOI: 10.1074/jbc.M111.253328. View

20.

Grossman M, Tworowski D, Dym O, Lee M, Levy Y, Murphy G . The intrinsic protein flexibility of endogenous protease inhibitor TIMP-1 controls its binding interface and affects its function. Biochemistry. 2010; 49(29):6184-92. DOI: 10.1021/bi902141x. View